• Data Shows Six Month Duration for Revance DaxibotulinumtoxinA

    2 monthes ago - By Surgical Aesthetics Magazine

    Revance Therapeutics announced results for two Phase 2a open-label, dose escalation studies of its investigational drug candidate DaxibotulinumtoxinA for Injection in the treatment of dynamic forehead lines following glabellar line injections and lateral canthal lines. Both studies demonstrated positive efficacy results and that DaxibotulinumtoxinA for Injection was well tolerated. Additionally, the studies evaluated a range of doses, providing directional guidance on the impact of dose on efficacy and duration of effect.
    In the forehead lines study, a total of 61 subjects were randomized...
    Read more ...